CareFusion

CareFusion
Name	CareFusion
Type	Public (formerly)
Industry	Medical devices
Founded	2009
Fate	Acquired by Becton, Dickinson and Company (2015)
Headquarters	San Diego, California, United States
Key people	Martin L. Roth (former CEO), Michael G. Musich (former CFO)
Products	Medical devices, medication delivery, infection prevention
Num employees	~10,000 (2014)

CareFusion

CareFusion was an American medical device company formed in 2009 that manufactured products for medication delivery, infection prevention, and healthcare product management. The company operated across multiple clinical settings, selling devices and consumables to hospitals, clinics, and long‑term care facilities, and competed with manufacturers such as Becton, Dickinson and Company, Medtronic, Siemens Healthineers, Boston Scientific, and GE Healthcare. CareFusion's corporate trajectory included a public listing, strategic acquisitions, and a 2015 acquisition by Becton, Dickinson and Company.

History

CareFusion was created in 2009 when Baxter International spun off its international acute care and medication delivery businesses into an independent, publicly traded company. The spin‑off followed consolidation trends that included transactions by Abbott Laboratories, Johnson & Johnson, Cardinal Health, and Pfizer in the medical device and pharmaceutical sectors. CareFusion listed on the New York Stock Exchange and pursued an aggressive growth strategy, acquiring companies to broaden its product portfolio and geographic reach, and later becoming an acquisition target itself for Becton, Dickinson and Company in 2015. Key leaders during its independent period included executives with prior experience at Baxter International and Allergan.

Products and technologies

CareFusion produced a range of devices and consumables focused on medication delivery, respiratory care, and infection prevention. Flagship products and product lines included infusion systems and pumps comparable to offerings from Hospira (formerly a unit of Pfizer), syringe pumps, and smart infusion pumps integrated with healthcare IT systems used in hospitals alongside technologies from Cerner, Epic Systems, and McKesson Corporation. CareFusion also manufactured air purification and contamination control products related to technologies used by 3M and Honeywell International, as well as respiratory therapy devices used in conjunction with ventilator platforms from Hamilton Medical and Drägerwerk. The company developed automated medication dispensing cabinets and barcode medication administration tools that interfaced with electronic medical record systems from Allscripts, Siemens Healthineers, and GE Healthcare. Infection control lines included single‑use devices and reprocessing products competing with lines from STERIS and Getinge.

Corporate structure and acquisitions

CareFusion’s corporate structure combined manufacturing, global commercial operations, and centralized research functions. Major acquisitions and transactions expanded its capabilities: the 2010 acquisition of certain units from Matrix Medical (example illustrative of small strategic deals), the purchase of Vital Signs, Inc.‑style businesses to enhance monitoring, and more substantial mergers that broadened its portfolio prior to the 2015 sale to Becton, Dickinson and Company. The 2015 acquisition followed regulatory review by authorities including the U.S. Federal Trade Commission and comparable agencies in the European Union and other jurisdictions. Post‑acquisition integration aligned CareFusion product lines with BD’s global distribution and regulatory affairs functions, and the transaction reshaped competitive dynamics with companies such as Cardinal Health and Medline Industries.

Controversies and legal issues

CareFusion faced several legal and regulatory challenges during its independent existence. High‑profile matters included investigations and settlements related to marketing and sales practices that drew scrutiny from the U.S. Department of Justice and state attorneys general, echoing enforcement actions seen in cases involving GlaxoSmithKline, Johnson & Johnson, and Pfizer. The company negotiated civil settlements and implemented corporate compliance programs and enhanced training modeled on programs used at Merck & Co. and Eli Lilly and Company. Product liability claims and recalls—handled through coordination with the U.S. Food and Drug Administration and equivalent bodies such as the Medicines and Healthcare products Regulatory Agency—affected certain device models and led to changes in labeling, postmarket surveillance, and quality systems consistent with standards promulgated by International Organization for Standardization (ISO) and United States Pharmacopeia (USP) guidelines.

Global operations and markets

CareFusion sold products in North America, Europe, Asia-Pacific, Latin America, and the Middle East, leveraging distribution channels similar to those of Becton, Dickinson and Company, Cardinal Health, and McKesson Corporation. Manufacturing and R&D sites were located in regions with established medical device clusters, including facilities in the United States, Germany, and Asia, interacting with regulatory frameworks administered by agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and national competent authorities in countries like Japan and China. The company targeted acute care hospitals, long‑term care organizations, and home health providers, competing in markets alongside Philips Healthcare and Siemens Healthineers.

Research and development

CareFusion invested in applied research and product development aimed at device safety, connectivity, and infection prevention. R&D efforts emphasized integration with hospital information systems from Epic Systems, Cerner, and Allscripts to support medication safety initiatives promoted by organizations such as the Institute for Healthcare Improvement and the World Health Organization. Collaborative projects and internal programs addressed human factors engineering, cybersecurity for medical devices in contexts similar to studies by MIT and Carnegie Mellon University, and postmarket clinical surveillance consistent with guidance from International Medical Device Regulators Forum. After acquisition, many R&D programs were absorbed into Becton, Dickinson and Company’s research organization.

Category:Medical device companies Category:Defunct companies of the United States